Dexcom Q3 revenue $994M (+2%); reiterates FY24 guidance; CCO retiring

DEXCOM INC

2024-Q3 EPS reported $1.04 revenue$2,919,500,000

Revenue $994.2M (+2% reported, +3% organic); U.S. down 2%, international up 12%.
GAAP net income $134.6M ($0.34 EPS); Non-GAAP $179.9M ($0.45 EPS). Operating margin contracted.
Launched Stelo OTC glucose biosensor in U.S.; Dexcom G7 in Australia, ONE+ in France.
FY24 guidance reaffirmed: revenue ~$4.00-4.05B, non-GAAP operating margin ~20%.
Teri Lawver, EVP & Chief Commercial Officer, retiring year-end; CEO Sayer leading commercial while search ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.